IMC Chicago
BIS icon

IMC Chicago’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

IMC Chicago’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-12,605
Closed -$443K – 2629
2024
Q1 		$443K Buy
12,605
+5,104
+68% +$180K ﹤0.01% 2098
2023
Q4 		$271K Buy
+7,501
New +$342K ﹤0.01% 1756
2022
Q4 		– Sell
-11,668
Closed -$590K – 1255
2022
Q3 		$590K Buy
11,668
+1,166
+11% +$55.2K ﹤0.01% 1058
2022
Q2 		$566K Buy
10,502
+1,168
+13% +$65.4K ﹤0.01% 947
2022
Q1 		$450K Buy
+9,334
New +$477K ﹤0.01% 1013
2021
Q4 		– Sell
-13,730
Closed -$495K – 1186
2021
Q3 		$495K Buy
13,730
+6,628
+93% +$231K ﹤0.01% 1108
2021
Q2 		$261K Buy
7,102
+362
+5% +$15.3K ﹤0.01% 1076
2021
Q1 		$304K Buy
6,740
+938
+16% +$39.4K ﹤0.01% 1001
2020
Q4 		$273K Buy
+5,802
New +$316K ﹤0.01% 1007

Other funds holding BIS

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IMC Chicago's BIS Position: Q2 2024 in Review

IMC Chicago sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q2 2024, closing a stake of 12,605 shares — an estimated $443K sold.

IMC Chicago first reported a position in BIS in Q4 2020 and held it in 9 quarters. The position peaked at $590K in Q3 2022. 6 funds tracked by Wall St. Rank hold BIS as of Q2 2024.

  • IMC Chicago reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q2 2024 after selling out during the quarter.
  • IMC Chicago sold 12,605 ProShares UltraShort NASDAQ Biotechnology shares in Q2 2024, an estimated $443K.
  • IMC Chicago first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2020 and held it in 9 quarters.
  • IMC Chicago's ProShares UltraShort NASDAQ Biotechnology position peaked at $590K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q2 2024.

Based on IMC Chicago's 13F filing for Q2 2024, filed 15 Jul 2024.